Binding of endothelin to plasma proteins and tissue receptors: effects on endothelin determination, vasoactivity, and tissue kinetics
- 2 October 1995
- journal article
- research article
- Published by Wiley in FEBS Letters
- Vol. 373 (1) , 97-101
- https://doi.org/10.1016/0014-5793(95)01017-9
Abstract
In vitro binding of (3-[125I]Tyr)-endothelin-1 ([125I]ET-1) and (3-[125I]Tyr)-big ET-1(1-38) ([125I]big ET-1) to plasma proteins of healthy humans, cardiac patients and normotensive and hypertensive rats was investigated by equilibrium dialysis. Binding of both tracers was similar in plasma from healthy humans, patients with congestive heart failure, and following myocardial infarction (approximately 60%), and marginally higher in rat plasmas (approximately 70%). Binding of [125I]ET-1 to human plasma could be explained by binding to human serum albumin. Endogenous plasma ET-1 levels were approximately 9 pg/ml in healthy humans, and approximately 12-16 pg/ml in cardiac patients; big ET-1 concentrations were approximately two- to threefold higher. ET-1 bound to plasma protein was partly lost in column extraction. In rat isolated perfused hearts, the coronary dilator and constrictor potency of exogenous free and albumin-bound ET-1 was similar, whereas the kinetics of endogenous ET-1 was impeded by tight binding to ET receptors. The data indicate that binding of ET-1 to plasma proteins is without effect on peptide vasoactivity, but binding to tissue receptors greatly impedes its tissue kinetics.Keywords
This publication has 17 references indexed in Scilit:
- Novel receptor antagonists welcome a new era in endothelin biologyTrends in Pharmacological Sciences, 1994
- Effect of intracellular Ca2+ concentration on endothelin‐1 secretionFEBS Letters, 1994
- Plasma endothelin-1 in acute myocardial infarction with heart failureAmerican Heart Journal, 1993
- Endothelin in Vascular and Endocrine Systems: Biological Activities and Its Mechanisms of Action.Endocrine Journal, 1993
- Methods of Determining Plasma and Tissue Binding of DrugsClinical Pharmacokinetics, 1992
- Endothelins and sarafotoxins: Physiological regulation, receptor subtypes and transmembrane signalingPharmacology & Therapeutics, 1992
- Increased endothelin in experimental heart failure.Circulation, 1990
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988
- Protein Binding as a Primary Determinant of the Clinical Pharmacokinetic Properties of Non-Steroidal Anti-Inflammatory DrugsClinical Pharmacokinetics, 1987
- Prazosin binding to human α1-acid glycoprotein (orosomucoid), human serum albumin, and human serum. Further characterization of the 'single drug binding site' of orosomucoidJournal of Pharmacy and Pharmacology, 1985